AAV Contract Development and Manufacturing Organizations Market by Product Type, Distribution Channel, End User 2024-2032
                     Global AAV Contract 
Development and 
Manufacturing Organizations 
Market Research and 
Forecast Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A cc o r d i ng  t o  t h e  l a te s t  r e p o r t  b y  I MA R C  Gr o u p ,  t i t l e d  " A A V  C o n t ra c t  D e v e l o p m e n t  
an d  M a n u f a c tu r i n g  O r g an i z a t io n s  Ma r k e t :  G lo b a l  I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  
Gr o w th ,  O p p o r t u n i t y  an d  F o re c a s t  2 0 2 4 -2 0 3 2 ,"  t he  g l o b a l  A A V  c o n t r a c t  d e v e l op m e n t  
an d  m an u f a c tu r i n g  o r g a n i z a t i o n s  m a r k e t  s i z e  r e a c he d  U S $  6 7 5 .1  M i l l i o n  i n  2 0 23 .
Report Fac tors  A f fect ing  the  Growt h  o f  t he  AAV Cont ract  Deve lopment  and  Manuf act ur ing  Organiz a t ions  Indust ry :
Advancement s  in  Gene Therapy :
Highlight and T he  g ro w i n g  de m a n d  fo r  A A V  ve c t o r s  i n  g e n e  th e r a p y  de l i v e r y  i s  o f f e r i n g  a  p o s i t i v e  
ma r k e t  o u t l o o k .  A d va n c e me n t s  i n  g e ne  t h e r a py  te c h n i qu e s  a r e  l e a d i ng  t o  t h e  
de v e l o p me n t  o f  m o re  so p h i s t i ca t e d  v ec t o r  d e s i g n s  a nd  d e l i v e r y  s t r a t eg i e s .  A A V  
Description de v e l o p me n t  a n d  m a nu f a c tu r i n g  o r ga n i z a t i on s  ( C D MO s )  a r e  c o n t i n u a l l y  a d ap t i n g  t h e i r  
ma n u f ac t u r i n g  p r o c e s se s  t o  a c c o mm o d a t e  t h e s e  ad v a n c em e n ts  an d  e ns u r e  t h e  
p r o d u c t i o n  o f  v e c t o rs  t h a t  m e e t  e v o l v i n g  s pe c i f i c a t i on s .  
I n  ad d i t i o n ,  A A V  C D M Os  a r e  l e v e r a g i n g  b i o p r o c e ss i n g  t e ch n o l o g i es ,  s u ch  a s  i mp r o v e d  
ce l l  c u l t u r e  s y s te m s ,  p u r i f i c a t i o n  me t h o d s ,  a n d  a na l y t i c s ,  t o  s t r e am l i n e  p ro d u c t i o n  
w o r k f l o w s  a n d  i n c r e a se  y i e l d  w h i l e  ma i n t a i n i n g  p r od u c t  qu a l i t y  an d  c on s i s t e n cy .
Outsourcing Trend:
The r i s ing  focus on  outsourc ing AAV vec tor  manufac tu r ing  i s  bo ls ter ing the 
marke t  g rowth .  In  add i t ion ,  b iopharmaceut ica l  companies  a re  leverag ing  the  
capab i l i t i es  o f  AAV CDMOs to  m i t iga te  r i sks ,  acce lera te  produc t ion 
t ime l ines,  and  a l loca te  resources more  e f f ic ien t l y .  
By ou tsourc ing ,  f i rms  can  access advanced manufactur ing technolog ies  and 
Report ensure  compl iance wi th  regu la to ry  s tandards  w i thou t  cap i ta l  investment .  
Th is  t rend underscores the s t ra teg ic  advantage  o f  par tner ing w i th  
Highlight and spec ia l ized  CDMOs,  enab l ing  pharmaceut ica l  compan ies  to  focus  on  core  
competenc ies  whi le  benef i t ing  f rom the  spec ia l i zed capabi l i t i es  o f fered  by  
AAV CDMOs.
Description Technological  Advancements:
Innovat ions in  AAV vecto r  p roduc t ion ,  pur i f i ca t ion ,  and  ana ly t i cs  are  
impe l l ing  the market  g rowth .  Advanced techno log ies  enhance  manufac tur ing 
e f f ic iency ,  sca lab i l i t y ,  and produc t  qua l i t y ,  meet ing  the  increas ing  demands 
o f  gene therapy deve lopers .  Bes ides  th is ,  CDMOs are  invest ing  in  nove l  
p la t fo rms and p rocesses to  ga in  a  compet i t i ve  edge and a t t rac t  c l ien ts  
seek ing  advanced manufactur ing so lu t ions .
Fur thermore ,  modu la r  b iop rocess ing  sys tems enab le  AAV CDMOs to  cus tomize  
manufac tu r ing  work f lows ,  op t im ize  resource  u t i l i za t ion ,  and  exped i te  p rocess  
deve lopment  and  sca le -up .  These  p la t fo rms fac i l i t a te  cos t -e f fec t ive  
manu fac tu r ing  so lu t ions ,  empower ing  AAV CDMOs to  mee t  the  evo lv ing  
demands o f  gene  the rapy .
Report 
Request  for  a  PDF sample  o f  th is  repor t :  
Highlight and h t tps : / /www. imarcgroup .com/aav-con t rac t -deve lopment -manu fac tu r ing -o rgan izat ions-marke t / reques tsamp le
Description
Report Description
Global  AAV Contract Development and Manufacturing Organizations Market Trends:
The growing demand for  AAV CDMO serv ices due to  the expanding p ipe l ine o f  gene therapy candidates  
across  therapeut ic  domains l ike rare  d iseases and onco logy is  pos i t ive ly  in f luenc ing the market .  In  
add i t ion,  b iopharmaceut ica l  companies are  increas ingly  seek ing spec ia l ized exper t ise and scalable  
manufactur ing solu t ions f rom CDMOs to  expedi te product  deve lopment  and commerc ia l izat ion.  
Bes ides th is ,  the r is ing inves tment  in  outsourc ing par tnerships to  e f f ic ient ly  nav igate  the complex i t ies  of  
AAV vec tor  product ion and pur i f icat ion is  bo ls ter ing the market  growth.  Fur thermore,  co l laborat ions  and 
par tnersh ips  between AAV CDMOs and b iopharmaceut ica l  companies ass is t  in  accelera t ing product  
development  and commerc ia l iza t ion.
View Report  TOC,  Figures and Tables :  
ht tps: / /www. imarcgroup.com/aav-contract-development-manufactur ing-organizat ions-market
Breakup by Workfl ow:
• Upstream Process ing
• Downstream Process ing
Breakup by Culture Type:
• Adherent  Culture
Report 
• Suspension Culture
Segmentation
Breakup by Application:
• Cel l  and Gene Therapy Development 
• Vaccine Development
• Biopharmaceutical  and Pharmaceutical  
Discovery
• Biomedical  Research
Breakup by End User:
• Pharmaceutical  and Biopharmaceutical  
Companies
• Academic and Research Insti tutes
Report Breakup by Region:
• North America
Segmentation
• Europe
• Asia-Pacifi c
• Latin America
• Middle East and Afr ica
• ABL Manufacturing ( Institut Mérieux)
• Asklepios BioPharmaceutical Inc. (Bayer AG)
• Anlongbio
• Bel ief Biome Inc.
Competitive 
• Catalent Inc.
Landscape • Charles River Laboratories International Inc.
with Key • Creative Biogene
• GenScript ProBio (GenScript Biotech 
Players Corporation)
• Merck KGaA
• Oxford Biomedica
• TFBS Bioscience Inc.
• Thermo Fischer Scientifi c Inc.
How has the global AAV contract development and 
manufacturing organizations market performed so far, 
and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in 
the global AAV contract development and 
manufacturing organizations market?
What is the impact of each driver, restraint, and 
opportunity on the global AAV contract development 
Key and manufacturing organizations market?
Questions What are the key regional markets?
Answered in 
Which countries represent the most attractive AAV 
contract development and manufacturing organizations 
the Report market?
What is the breakup of the market based on the 
workflow?
Which is the most attractive workflow in the AAV 
contract development and manufacturing organizations 
market?
What is the breakup of the market based on the culture 
type?
Which is the most attractive culture type in the AAV 
contract development and manufacturing organizations 
market?
What is the breakup of the market based on the 
application?
Key Which is the most attractive application in the AAV contract development and manufacturing organizations 
market?
Questions 
What is the breakup of the market based on the end 
Answered in user?
the Report Which is the most attractive end user in the AAV 
contract development and manufacturing organizations 
market?
What is the competitive structure of the global AAV 
contract development and manufacturing organizations 
market?
Who are the key players/companies in the global AAV 
contract development and manufacturing organizations 
market?
1     P r e f a c e
2  S c o p e  a n d  M e t h o d o l o g y
2 . 1  O b j e c t i v e s  o f  t h e  S t u d y
2 . 2  S t a k e h o l d e r s
2 . 3  D a t a  S o u r c e s
2 . 3 . 1  P r i m a r y  S o u r c e s
2 . 3 . 2  S e c o n d a r y  S o u r c e s
2 . 4  M a r k e t  E s t i m a t i o n
2 . 4 . 1  B o t t o m - U p  A p p r o a c h
Table of 2 . 4 . 2  T o p - D o w n  A p p r o a c h2 . 5  F o r e c a s t i n g  M e t h o d o l o g y
3  E x e c u t i v e  S u m m a r y
4  G l o b a l  A A V  C o n t r a c t  D e v e l o p m e n t  A n d  M a n u f a c t u r i n g  O r g a n i z a t i o n s  M a r k e t  -  
I n t r o d u c t i o n
Contents 4 . 1  O v e r v i e w4 . 2  M a r k e t  D y n a m i c s
4 . 3  I n d u s t r y  T r e n d s
4 . 4  C o m p e t i t i v e  I n t e l l i g e n c e
5  G l o b a l  A A V  C o n t r a c t  D e v e l o p m e n t  A n d  M a n u f a c t u r i n g  O r g a n i z a t i o n s  M a r k e t  
L a n d s c a p e
5 . 1  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
5 . 2  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6  G l o b a l  A A V  C o n t r a c t  D e v e l o p m e n t  A n d  M a n u f a c t u r i n g  O r g a n i z a t i o n s  M a r k e t  -  
B r e a k u p  b y  W o r k f l o w
6 . 1  U p s t r e a m  P r o c e s s i n g
6 . 1 . 1  O v e r v i e w
6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
6 . 1 . 3  M a r k e t  S e g m e n t a t i o n
6 . 1 . 3 . 1  V e c t o r  A m p l i f i c a t i o n  a n d  E x p a n s i o n
6 . 1 . 3 . 2  V e c t o r  R e c o v e r y  a n d  H a r v e s t i n g
6 . 1 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
       
6 . 2  D o w n s t r e a m  P r o c e s s i n g
6 . 2 . 1  O v e r v i e w
6 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
6 . 2 . 3  M a r k e t  S e g m e n t a t i o n
6 . 2 . 3 . 1  P u r i f i c a t i o n
6 . 2 . 3 . 2  F i l l  F i n i s h
6 . 2 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6 . 3  A t t r a c t i v e  I n v e s t m e n t  P r o p o s i t i o n  b y  W o r k f l o w
7  G l o b a l  A A V  C o n t r a c t  D e v e l o p m e n t  A n d  M a n u f a c t u r i n g  
O r g a n i z a t i o n s  M a r k e t  -  B r e a k u p  b y  C u l t u r e  T y p e
7 . 1  A d h e r e n t  C u l t u r e
Table of 7 . 1 . 1  O v e r v i e w7 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
7 . 1 . 3  M a r k e t  S e g m e n t a t i o n
7 . 1 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
Contents 7 . 2  S u s p e n s i o n  C u l t u r e7 . 2 . 1  O v e r v i e w
7 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
7 . 2 . 3  M a r k e t  S e g m e n t a t i o n
7 . 2 . 3 . 1  C h e m i s t r y  A n a l y z e r s
7 . 2 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
7 . 4  A t t r a c t i v e  I n v e s t m e n t  P r o p o s i t i o n  b y  C u l t u r e  T y p e
8  G l o b a l  A A V  C o n t r a c t  D e v e l o p m e n t  A n d  M a n u f a c t u r i n g  
O r g a n i z a t i o n s  M a r k e t  -  B r e a k u p  b y  A p p l i c a t i o n
8 . 1  C e l l  a n d  G e n e  T h e r a p y  D e v e l o p m e n t
8 . 1 . 1  O v e r v i e w
8 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
8 . 1 . 3  M a r k e t  S e g m e n t a t i o n
8 . 1 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /a a v- c o n t ra c t -d ev e l o pm ent -m a nu
fa c t u r i ng - o rga n i z a t i o ns -ma rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: